Cargando…
Do PD-1 and PD-L2 expressions have prognostic impact in hematologic malignancies?
BACKGROUND/AIM: PD-1 (programmed death-1) is an immune checkpoint receptor that modulates T-cell activity in peripheral tissues via interaction with its ligands, PD-L1 (programmed death-ligand 1) and PD-L2 (programmed death-ligand 2). Tumor cells upregulate PD-L1 or PD-L2 to inhibit this T lymphocyt...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Scientific and Technological Research Council of Turkey
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350792/ https://www.ncbi.nlm.nih.gov/pubmed/30761875 http://dx.doi.org/10.3906/sag-1706-194 |